Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05429827
Other study ID # B-BR-110-078
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 18, 2022
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source National Cheng-Kung University Hospital
Contact Ta-Shen Kuan, M.D., M.S.
Phone 886-6-2353535
Email kuan@mail.ncku.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with an myofascial trigger point (MTrP) in their upper trapezius will be divided into three groups: Group A receiving MTrP injection with normal saline (control group), Group B with hypo-osmolar dextrose (5% dextrose), and Group C with hyper-osmolar dextrose (15% dextrose). Clinical outcomes and morphological changes will be measured before the injection, one hour after, one week after, two weeks after, and one month after the injection to delineate the therapeutic effects of dextrose injection for an MTrP.


Description:

This experiment is designed to evaluate the therapeutic effects of dextrose injection on an myofascial trigger point (MTrP). Patients with an MTrP in their upper trapezius will be recruited and be divided into three groups: Group A receiving MTrP injection with normal saline (control group), Group B with hypo-osmolar dextrose (5% dextrose), and Group C with hyper-osmolar dextrose (15% dextrose). Clinical outcomes (visual analog scale, pressure pain threshold, range of motion, neck disability index) will be measured before the injection, one hour after, one week after, two weeks after, and one month after the injection. Morphological changes of an MTrP before, and after the injection will also be evaluated by sonography. Through this study, the definite therapeutic effects, and the better osmolality of dextrose injection for the treatment of an MTrP will be delineated.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date December 20, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - 1). Patients should be 20 years of age or older; - 2). They are able to communicate freely; - 3). Patients have the diagnosis of myofascial pain syndrome (MPS) with a definite myofascial trigger point (MTrP) in the neck base and upper back regions (the upper trapezius muscle). The MTrP is identi?ed based on the following criteria, as recommended by Simons [Simons et al., 1999]: - (a). a localized tender spot in a palpable taut band of muscle ?bers, - (b). recognized pain (as the usual clinical complaint) when the tender spot is compressed, - (c). characteristic and consistent referred pain. - 4). Symptoms of MPS should be more than 3 weeks. Exclusion Criteria: - (1). acute or serious medical problems; - (2). cognitive impairment or psychiatric disorder; - (3). coagulopathy or any other bleeding disorder; - (4). taking medication of anticoagulation or antithrombolytics; - (5). sensory deficiency over the body part where MTrPs located; - (6). serum hepatitis B or acquired immunode?ciency syndrome; - (7). malignancy; - (8). pregnant or likely to be pregnant. - (9). diabetes mellitus

Study Design


Intervention

Other:
normal saline
Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Drug:
Dextrose 5% in water
Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Dextrose 15% in water
Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.

Locations

Country Name City State
Taiwan Department of physical Medicine and Rehabilitation, National Cheng Kung University Hospital Tainan

Sponsors (1)

Lead Sponsor Collaborator
National Cheng-Kung University Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (5)

Chou Y, Chiou HJ, Wang HK, Lai YC. Ultrasound-guided dextrose injection treatment for chronic myofascial pain syndrome: A retrospective case series. J Chin Med Assoc. 2020 Sep;83(9):876-879. doi: 10.1097/JCMA.0000000000000339. — View Citation

Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016 Jul 7;9:139-59. doi: 10.4137/CMAMD.S39160. eCollection 2016. — View Citation

Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil. 1998 Jul;79(7):863-72. doi: 10.1016/s0003-9993(98)90371-9. — View Citation

Hong CZ. Treatment of myofascial pain syndrome. Curr Pain Headache Rep. 2006 Oct;10(5):345-9. doi: 10.1007/s11916-006-0058-3. — View Citation

Kuan TS, Chen JT, Chen SM, Chien CH, Hong CZ. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil. 2002 Jul;81(7):512-20; quiz 521-3. doi: 10.1097/00002060-200207000-00008. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary visual analog scale (VAS) To measure the pain intensity of a myofascial trigger point. The minimum value is 0, and the maximum value is 10, and higher scores mean worse outcome (more painful). Change from Baseline visual analog scale at one hour after intervention.
Primary visual analog scale (VAS) To measure the pain intensity of a myofascial trigger point. The minimum value is 0, and the maximum value is 10, and higher scores mean worse outcome (more painful). Change from Baseline visual analog scale at one week after intervention.
Primary visual analog scale (VAS) To measure the pain intensity of a myofascial trigger point. The minimum value is 0, and the maximum value is 10, and higher scores mean worse outcome (more painful). Change from Baseline visual analog scale at two weeks after intervention.
Primary visual analog scale (VAS) To measure the pain intensity of a myofascial trigger point. The minimum value is 0, and the maximum value is 10, and higher scores mean worse outcome (more painful). Change from Baseline visual analog scale at one month after intervention.
Secondary pressure pain threshold (PPT) To measure the change of pressure pain threshold of a myofascial trigger point. The minimum value is 0 Kg/cm2, the maximum value is 5 Kg/cm2, and higher scores mean better outcome (less painful). Change from Baseline pressure pain threshold at one hour after intervention.
Secondary pressure pain threshold (PPT) To measure the change of pressure pain threshold of a myofascial trigger point. The minimum value is 0 Kg/cm2, the maximum value is 5 Kg/cm2, and higher scores mean better outcome (less painful). Change from Baseline pressure pain threshold at one week after intervention.
Secondary pressure pain threshold (PPT) To measure the change of pressure pain threshold of a myofascial trigger point. The minimum value is 0 Kg/cm2, the maximum value is 5 Kg/cm2, and higher scores mean better outcome (less painful). Change from Baseline pressure pain threshold at two weeks after intervention.
Secondary pressure pain threshold (PPT) To measure the change of pressure pain threshold of a myofascial trigger point. The minimum value is 0 Kg/cm2, the maximum value is 5 Kg/cm2, and higher scores mean better outcome (less painful). Change from Baseline pressure pain threshold at one month after intervention.
Secondary Range of motion (ROM) of the neck To measure the change of the range of motion of cervical spine. The minimum value is 0 degree, the maximum value is 90 degree, and higher scores mean better outcome. Change from Baseline range of motion (ROM) of the neck at one hour after intervention.
Secondary Range of motion (ROM) of the neck To measure the change of the range of motion of cervical spine. The minimum value is 0 degree, the maximum value is 90 degree, and higher scores mean better outcome. Change from Baseline range of motion (ROM) of the neck at one week after intervention.
Secondary Range of motion (ROM) of the neck To measure the change of the range of motion of cervical spine. The minimum value is 0 degree, the maximum value is 90 degree, and higher scores mean better outcome. Change from Baseline range of motion (ROM) of the neck at two weeks after intervention.
Secondary Range of motion (ROM) of the neck To measure the change of the range of motion of cervical spine. The minimum value is 0 degree, the maximum value is 90 degree, and higher scores mean better outcome. Change from Baseline range of motion (ROM) of the neck at one month after intervention.
Secondary neck disability index (NDI) To measure the change of neck disability index (NDI) related to the myofascial trigger point. The minimum value is 0, the maximum value is 50, and higher scores mean worse outcome (increased functional disability). Change from Baseline neck disability index (NDI) at one hour after intervention.
Secondary neck disability index (NDI) To measure the change of neck disability index (NDI) related to the myofascial trigger point. The minimum value is 0, the maximum value is 50, and higher scores mean worse outcome (increased functional disability). Change from Baseline neck disability index (NDI) at one week after intervention.
Secondary neck disability index (NDI) To measure the change of neck disability index (NDI) related to the myofascial trigger point. The minimum value is 0, the maximum value is 50, and higher scores mean worse outcome (increased functional disability). Change from Baseline neck disability index (NDI) at two weeks after intervention.
Secondary neck disability index (NDI) To measure the change of neck disability index (NDI) related to the myofascial trigger point. The minimum value is 0, the maximum value is 50, and higher scores mean worse outcome (increased functional disability). Change from Baseline neck disability index (NDI) at one month after intervention.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06029413 - Myo vs. Myofascial Injection for Myofascial Trigger Points N/A
Recruiting NCT04985578 - Effects on Muscle Activity After Dry Needling in Myofascial Trigger Points of the Gastrocnemius Muscles N/A
Completed NCT05546203 - Trigger Point Treatment in Chronic Pelvic Pain N/A
Completed NCT06258070 - Clinical Performance of Therapeutic Use of BTX for Bruxism N/A
Completed NCT04531306 - An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band N/A
Completed NCT03708107 - Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points N/A
Completed NCT02913976 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain N/A
Completed NCT02913963 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point N/A
Completed NCT04719689 - Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis N/A
Recruiting NCT05792111 - Caudal Epidural Steroid and Trigger Point Injection Phase 4
Completed NCT03704311 - Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry N/A
Recruiting NCT05151510 - Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department Phase 4
Completed NCT05396196 - An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band N/A
Completed NCT05664165 - The Efficiency of Dry Needling and Cold Spray-stretching Treatments N/A
Completed NCT01250184 - Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Phase 4
Enrolling by invitation NCT03941054 - Myosfascial Trigger-Points and Effects on Neuromuscular Response N/A
Completed NCT04993118 - Integration of Neuromuscular Inhibition Technique On Trapezius Trigger Points. N/A
Completed NCT04851743 - Effects on Neuromuscular Function After Dry Needling in Myofascial Trigger Points in the Gastrocnemius Muscles N/A
Not yet recruiting NCT06338514 - The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome. N/A
Recruiting NCT06013644 - Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome Early Phase 1